Skip to main content
Equibles

NOVELIX · NOVELIX PHARMACEUTICALS LIMITE · Financials

Use NOVELIX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NOVELIX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
70.05 INR +0.93 (+1.35%) At close · Nov 13
Rebalance outlook locked
Market Cap
1.99B INR
Shares
28.47M
Volume · Nov 13 13.63K Avg daily vol (3M) 4387

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
1.32B +330.7%
FY2026 Revenue FY2025–FY2026
Net Income
25.57M +2925.6%
FY2026 Net Income FY2025–FY2026
Operating Cash Flow
-223.89M -63.6%
FY2026 Operating Cash Flow FY2025–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2026 FY2025
INR 1.55B 1.32B 307.19M
INR 2.75M 1.01M 380K
INR 2.45M 0 0
INR 54.98M 34.04M 1.23M
INR 8.39M 8.48M 388K
INR 46.58M 25.57M 845K
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2025–FY2026: 0 in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.